These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The cardiovascular and metabolic complications of HIV infection. Krishnaswamy G; Chi DS; Kelley JL; Sarubbi F; Smith JK; Peiris A Cardiol Rev; 2000; 8(5):260-8. PubMed ID: 11174904 [TBL] [Abstract][Full Text] [Related]
6. Cardiovascular disease in HIV infection. Sánchez-Torres RJ; García-Palmieri MR P R Health Sci J; 2006 Sep; 25(3):249-54. PubMed ID: 17203795 [TBL] [Abstract][Full Text] [Related]
7. Lipodystrophy, insulin resistance, diabetes mellitus, dyslipidemia, and cardiovascular disease in human immunodeficiency virus infection. Tanwani LK; Mokshagundam SL South Med J; 2003 Feb; 96(2):180-8; quiz 189. PubMed ID: 12630645 [TBL] [Abstract][Full Text] [Related]
8. Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors. Boccara F AIDS; 2008 Sep; 22 Suppl 3():S19-26. PubMed ID: 18845918 [TBL] [Abstract][Full Text] [Related]
9. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy. Falutz J Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):651-61. PubMed ID: 17710086 [TBL] [Abstract][Full Text] [Related]
10. Cardiovascular disease and toxicities related to HIV infection and its therapies. Zareba KM; Miller TL; Lipshultz SE Expert Opin Drug Saf; 2005 Nov; 4(6):1017-25. PubMed ID: 16255661 [TBL] [Abstract][Full Text] [Related]
11. Management of metabolic complications and cardiovascular risk in HIV-infected patients. Blanco F; San Román J; Vispo E; López M; Salto A; Abad V; Soriano V AIDS Rev; 2010; 12(4):231-41. PubMed ID: 21179187 [TBL] [Abstract][Full Text] [Related]
12. [Emergencies in HIV infection]. Burckhardt B; Battegay M Ther Umsch; 1998 May; 55(5):295-301. PubMed ID: 9643127 [TBL] [Abstract][Full Text] [Related]
13. Antiretroviral therapy with heart. Randell P; Moyle G Am J Ther; 2009; 16(6):579-84. PubMed ID: 19940610 [TBL] [Abstract][Full Text] [Related]
14. Cardiac effects in perinatally HIV-infected and HIV-exposed but uninfected children and adolescents: a view from the United States of America. Lipshultz SE; Miller TL; Wilkinson JD; Scott GB; Somarriba G; Cochran TR; Fisher SD J Int AIDS Soc; 2013 Jun; 16(1):18597. PubMed ID: 23782480 [TBL] [Abstract][Full Text] [Related]
15. [Cardiovascular risk in HIV infected patients]. Raimundo P; Miranda A; Ribeiro J; Mansinho K Acta Med Port; 2010; 23(4):669-76. PubMed ID: 20687996 [TBL] [Abstract][Full Text] [Related]
16. Cardiovascular effects of antiretroviral therapy and noninvasive assessments of cardiovascular disease in HIV infection. Cotter BR; Torriani FJ Cardiovasc Toxicol; 2004; 4(3):281-6. PubMed ID: 15470275 [TBL] [Abstract][Full Text] [Related]
19. Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy. Kovacic JC; Martin A; Carey D; Wand H; Mallon PW; Feneley MP; Emery S; Cooper DA; Carr A; Antivir Ther; 2005; 10(1):135-43. PubMed ID: 15751771 [TBL] [Abstract][Full Text] [Related]
20. Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival. Leonard EG; McComsey GA Infect Dis Clin North Am; 2005 Sep; 19(3):713-29. PubMed ID: 16102657 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]